Ozempic®, Wegovy®, Mounjaro® & Other GLP-1 Drugs Linked to
Gastroparesis, Bowel Obstruction & Severe GI Injuries
If you used Ozempic, Wegovy, Mounjaro, Zepbound or any GLP-1 receptor agonist and developed stomach paralysis (gastroparesis), intestinal blockage, ileus, or other serious gastrointestinal complications, you may be entitled to significant compensation.
Quick Eligibility Check
What Are GLP-1 Drugs?
GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) are injectable medications originally approved for type 2 diabetes and now widely prescribed for weight loss. Manufactured by Novo Nordisk and Eli Lilly, these drugs slow digestion and suppress appetite.
While effective for weight loss, thousands of patients have reported severe, life-altering gastrointestinal side effects that were not adequately warned about.
GLP-1 Drugs Linked to Gastroparesis & Severe GI Injuries
These medications dramatically slow gastric emptying. In some patients this leads to stomach paralysis (gastroparesis), intestinal blockages, ileus, and other dangerous complications that can require hospitalization or surgery.
Serious Complications
Gastroparesis (stomach paralysis), bowel obstruction, ileus, severe nausea/vomiting, malnutrition, gallbladder disease, pancreatitis, and in some cases vision loss (NAION).
Strong Scientific Evidence
- Multiple studies link GLP-1 drugs to slowed gastric emptying
- FDA adverse event reports continue to surge
- Risk persists even after stopping the medication
Manufacturers’ Alleged Failure
Novo Nordisk and Eli Lilly are accused of knowing about these severe risks but failing to provide adequate warnings to patients and doctors.
Current Ozempic / GLP-1 Mass Tort Status
As of May 2026 – and growing rapidly
In re: Ozempic (Semaglutide) & Related GLP-1 Products Liability Litigation – MDL 3094
Presided over by Judge Gene E.K. Pratter in the Eastern District of Pennsylvania. Bellwether trials are scheduled for late 2026. This is one of the fastest-growing pharmaceutical mass torts in the country.
Why victims are winning compensation:
- Failure to warn about gastroparesis and GI risks
- Inadequate pre- and post-market safety testing
- Misleading marketing of “safe” weight-loss drugs
Do You Qualify for the Ozempic / GLP-1 Lawsuit?
Most qualifying patients meet these criteria:
Ozempic, Wegovy, Mounjaro, Zepbound or similar for diabetes or weight loss
Gastroparesis, bowel obstruction, ileus, or other severe gastrointestinal complications
*Not everyone who used these drugs will qualify. A free review is required to confirm eligibility.
Get Your FREE Case Review
Takes less than 60 seconds. Our team will review your information and connect you with top mass tort attorneys.
Frequently Asked Questions
How much compensation can I expect?
Settlement amounts vary based on the severity of injury, duration of use, medical expenses, and long-term complications. Similar pharmaceutical mass torts have resulted in substantial recoveries. Final values will be determined after bellwether trials.
How long do I have to file?
Statutes of limitations vary by state and often depend on when the injury was discovered. Many states allow claims under the “discovery rule.” Contact us today to protect your rights.
What if I no longer have the medication packaging?
Our team works with medical record retrieval services at no cost to you. Pharmacy records, doctor notes, and insurance claims are usually enough to prove use and eligibility.
Do I have to go to court?
The vast majority of these cases settle out of court. You will likely never need to appear in person.
Don’t Wait — Ozempic / GLP-1 Cases Are Moving Fast
Bellwether trials are scheduled for 2026. Secure your place in the litigation before the next wave of resolutions.
PPC Squared Mass Torts • Franklin, TN • We connect qualified victims with the nation’s leading mass tort law firms